Stocky turns companies like Telix Pharmaceuticals Limited into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →How safely Telix Pharmaceuticals Limited is financed, graded A++ (strongest) to C from the last five years of accounts: debt against earnings, interest cover, cash against debt, how high and steady profit margins are, return on capital, and whether it generated cash every year. Not part of the Stocky score.
Every stock is scored across six dimensions built to answer one question — can this business keep compounding? — without a Bloomberg subscription. Here's the actual snapshot for Telix Pharmaceuticals Limited:
Quality + moat + leadership + valuation fused into a single 0–100 number. When you see a Verdict/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
We don't claim a backtest. The top-scoring basket is recorded every month and measured against the S&P 500 from that date onward — judged on what it said before the outcome was known. The record is young, and published as it stands.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Telix Pharmaceuticals Limited is under analysis by Stocky. Once the full Verdict is calculated, this page updates automatically with a 0–100 score, band (Buy / Hold / Avoid), and the specific thesis.
The Stocky Verdict for TLPPF is being computed. It's a 0–100 composite score built from the Compounder Score (business quality), Moat Score, Leadership Alignment and valuation vs peers.
Stocky hasn't finalised a Moat Score for Telix Pharmaceuticals Limited yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
Leadership Alignment for Telix Pharmaceuticals Limited is under analysis. Stocky scores founder tenure, insider ownership, CEO compensation multiple-of-salary, and long-term shareholder value creation.
Resilience Profile for Telix Pharmaceuticals Limited covers customer concentration, supply chain risk, refinancing walls, and regulatory exposure. Not yet finalised.
Sign up free and unlock the full analysis on TLPPF — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for TLPPF in the app.
